Pacific Shuanglin Bio-pharmacy: 2024 Interim Performance Forecast

Sensex a shareJul 10 12:00 ET · Announcements

Pacific Shuanglin Bio-Pharmacy (000403.SZ): Net income for the first half of the year is expected to increase by 120%-140%.

On July 10th, GeLongHui reported that Pacific Shuanglin Bio-Pharmacy (stock code 000403.SZ) released its forecast for the results of the first half of 2024, with a net income attributable to shareholders of the listed company of 0.315 billion yuan-0.344 billion yuan, a year-on-year increase of 120% -140%; net income after deducting non-recurring gains and losses of 0.281 billion yuan-0.313 billion yuan, a year-on-year increase of 170% -200%; basic earnings per share of 0.4309 yuan/share-0.4700 yuan/share. The main reason for the performance growth is the strong demand for sales in the blood products market, and the year-on-year growth of raw material plasma collection is good, in 2024.

Gelonghui FinanceJul 10 04:32 ET

Getting In Cheap On Pacific Shuanglin Bio-pharmacy Co., LTD (SZSE:000403) Is Unlikely

There wouldn't be many who think Pacific Shuanglin Bio-pharmacy Co., LTD's (SZSE:000403) price-to-earnings (or "P/E") ratio of 28.8x is worth a mention when the median P/E in China is similar at about

Simply Wall StJun 28 18:04 ET

Pacific Shuanglin Bio-Pharmacy (000403.SZ) will distribute a profit of 1.999 yuan per share for 10 shares in 2023, with a registration date of June 27.

Pacific Shuanglin Bio-pharmacy (000403.SZ) announced that the profit distribution plan for 2023 is based on a total of 731,074,913 shares that actually participated in profit distribution. Each shareholder will receive RMB 1.999297 in cash (tax included) for every 10 shares held. The equity dividend registration date for this distribution is June 27, 2024, and the ex-dividend date is June 28, 2024.

Gelonghui FinanceJun 21 04:17 ET

Pacific Shuanglin Bio-pharmacy (SZSE:000403) Seems To Use Debt Quite Sensibly

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to consider debt, when you think about how risky any given stock is, because too much

Simply Wall StJun 10 19:39 ET

Huaxin Securities: Both the supply and demand sides of blood products continue to improve, and the scale effect of leading companies gradually emerges.

According to the research reports released by Huaxin Securities, with the support and attention of domestic policies, the planning of new plasma stations such as the "14th Five-Year Plan" will gradually be implemented, and the construction of plasma stations will accelerate. China's plasma collection scale will continue to increase. In 2023, the plasma collection volume will exceed 12079 tons, an increase of more than 18.6% compared with 2022. Blood products belong to essential pharmaceuticals, and the entire industry is a licensed business, which determines its natural high policy barrier characteristics. The scale of plasma collection, the comprehensive utilization rate of blood plasma, and the profit-making ability of blood plasma are the core factors. The scale of plasma collection directly determines the scale of the enterprise. The number of existing varieties and research products are used to determine the comprehensive utilization rate and profit-making ability of blood plasma.

Zhitong FinanceJun 7 03:23 ET